Skip to content
#gene editing Review

Prime Editing and Its Delivery: Recent Advances in Gene Correction for Genetic Diseases.

Sep 2026 · Current Gene Therapy · 0 citations
Medicine

TL;DR

This review systematically summarizes the key improvements and evolutionary progress in the prime editor design and its updated delivery systems, with a particular focus on innovative modifications that have successfully overcome technical barriers.

Abstract

Prime editing (PE), as a transformative genome-editing technology, overcomes many of the limitations of CRISPR-Cas9, particularly by enabling high-fidelity base conversions independent of double-strand breaks (DSBs). This unique mechanism significantly reduces unintended insertions, deletions, and chromosomal rearrangements, positioning PE as a safer and more precise tool for therapeutic gene correction. Recently, the world's first FDA-approved PE clinical trial (PM359 for chronic granulomatous disease) was officially launched, representing a major milestone in the field and highlighting the growing clinical translational potential of PE for treating human genetic disorders. Since the introduction of PE technology, extensive research efforts have been devoted to improving its gene correction efficiency, expanding the editing window, broadening target-site compatibility, reducing the size of the editing protein, and optimizing in vivo delivery vector systems. This review systematically summarizes the key improvements and evolutionary progress in the prime editor design and its updated delivery systems, with a particular focus on innovative modifications that have successfully overcome technical barriers. This study also highlights recent advances in engineered PE variants and their derivative systems, which have collectively expanded the scope and precision of PE-mediated gene correction. Additionally, this study critically discusses the remaining limitations and challenges associated with its application.

View source

Similar papers

#gene editing Review Sep 2026

Precision Genome Engineering in Human Disease: Expanding Therapeutic Roles of CRISPR Technologies

This study provides a comprehensive analysis of recent literature on CRISPR-based genome editing, emphasizing next-generation modalities like base editing and prime editing, and their impact on target specificity and genomic integrity.

Abraham E. Ubhenin, F. Adamude, D. O. Ochalefu et al. · 0 citations
#gene editing Review Sep 2026

CRISPR–Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus

Recent advances in CRISPR-Cas9–mediated genome editing are highlighted, emphasizing breakthroughs in primary cell editing and the development of translational models for genetic diseases and diabetes mellitus.

Md Nur Islam, Md. Mahmudul Islam, Han Feng et al. · 0 citations
Review Open access

Prime Editing: An Overview.

Significant challenges remain for its broad applicability as a potential curative therapy for human genetic diseases, mainly related to ensuring efficient and safe delivery to target tissues.

Emilio M. García-Tenorio, Mar Álvarez, Eva Richard et al. · 0 citations
Review Dec 2024

Journal of Population Therapeutics & Clinical Pharmacology

This review starts by examining the advantages and limitations of various physical methods for delivering Cas9, and highlights key applications of CRISPR systems in epigenetic modifications, and explores the use of CRISPR-Cas9 technology in genome editing, with a particular focus on base editing and prime editing.

Suhail Ahmad Sheikh, W. Shah, Azka Khan et al. · 0 citations

Related blog posts

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.